FGEN (FibroGen, Inc.) Multiplikator Forward P/S
Demand for medical developments remains stable, yet biotech success is tied to liquidity levels. The forward P/S of FibroGen, Inc. (FGEN) reflects the asset's value dynamics, where the current status is 4.70. Delisting risks and a capital shortage following the pamrevlumab collapse are weighing on the share price, while roxadustat sales in China and the partnership with AstraZeneca create growth potential.
FGEN (FibroGen Corporation): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas FibroGen, Inc.|FGEN - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal FibroGen, Inc.|FGEN - Tanggungan utang total perusahaan|Utang-utang marang kapitalisasi buku FibroGen Corporation|FGEN - Utang jangka dawa|Utang jangka cendhak perusahaan FibroGen|Indikator likuiditas cepet fibrogen.com
- rincian asil keuangan lan kelipatan valuasi:
FGEN - Bathi pungkasan|Proyeksi bathi mangsa ngarep FibroGen, Inc.|FGEN - Periode bali modal bisnis|Rega marang bathi mangsa ngarep FibroGen Corp|FGEN - Rasio P/E diaturake wutah|Pangali EV/EBITDA FibroGen Corporation|FGEN - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan FibroGen|FGEN - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan fibrogen.com|FGEN - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep FibroGen, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis dhasar perusahaan:FibroGen FGEN
This indicator reflects the market valuation of the business relative to projected annual revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward P/S ratio on the GURU.Markets platform, an investor can evaluate the extent to which the pricing power of FibroGen, Inc. (FGEN), driven by the patent protection of its drugs, justifies the company's current market capitalization in the eyes of the market.
Analisis pesaing
Multiplikator Forward P/S HLN (Haleon)|KVUE (Kenvue Inc) - Rega mangsa ngarep marang pendapatan|Verona Pharma Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Jyong Bio MENS|LGND: Multiplikator Forward P/S|AMRX (amneal.com) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Perrigo|ALVO: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|GLPG - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals)|Prakiraan rega marang pendapatan mannkindcorp.com|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pacira Pharmaceuticals|ARS Pharma (SPRY) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TBPH|Multiplikator forward rega marang pendapatan AQST|SCPH: Rega forward marang dodolan|Multiplikator Forward P/S TECX|Rasio kapitalisasi marang dodolan sing dikarepake Tonix Pharma|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|EPRX: Kapitalisasi marang prakiraan pendapatan|BioHarvest Sciences - Multiplikator Forward P/S|invizyne.com (EXOZ) - Multiplikator forward rega marang pendapatan|ORMP (oramed.com) - Multiplikator forward rega marang pendapatan|ENTX - Rasio kapitalisasi marang dodolan sing dikarepake|HYFT (MindWalk) - Multiplikator Forward P/S|ABVC BioPharma, Inc - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CPIX|quantumbiopharma.com (QNTM) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings (RANI) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SNYR - Rasio rega marang prakiraan pendapatan|RLYB (Rallybio Corporation) - Kapitalisasi marang prakiraan pendapatan|lexariabioscience.com (LEXX) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan PULM (pulmatrix.com)|PTHL (Pheton Holdings Limited) - Multiplikator Forward P/S|APM: Rega forward marang dodolan|Multiplikator Forward P/S LYRA|Multiplikator Forward P/S Impact BioMedical, Inc. (IBO)|Rasio rega marang prakiraan pendapatan TNF Pharmaceuticals, Inc. TNFA|Rega forward marang dodolan YCBD|PRFX - Rasio rega marang prakiraan pendapatan|Altamira Therapeutics (CYTO) - Multiplikator forward rega marang pendapatan|LIPO: Multiplikator Forward P/S|OptiNose Corp (OPTN) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan PIRS|PROC: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|QLI - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ACELYRIN, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake TFFP (TFF Pharmaceuticals, Inc)
